Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 2000 Jun;90(6):966–971. doi: 10.2105/ajph.90.6.966

Menopausal hormones and breast cancer in a biracial population.

P G Moorman 1, H Kuwabara 1, R C Millikan 1, B Newman 1
PMCID: PMC1446270  PMID: 10846517

Abstract

OBJECTIVES: This study examined the association between menopausal hormones and breast cancer in a biracial population. METHODS: Logistic regression was used to calculate odds ratios for breast cancer associated with hormone use among 397 cases and 425 controls, all menopausal women. RESULTS: Odds ratios for ever use of hormones were 0.8 (95% confidence interval [CI] = 0.5, 1.2) for White women and 0.7 (95% CI = 0.4, 1.2) for Black women. Risk was not increased with longer duration of use or more recent use. CONCLUSIONS: Breast cancer risk was not increased among White or Black women who used menopausal hormones, despite patterns of use varying considerably between races.

Full Text

The Full Text of this article is available as a PDF (83.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldrich T. E., Vann D., Moorman P. G., Newman B. Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registry. Breast Cancer Res Treat. 1995 Jul;35(1):61–64. doi: 10.1007/BF00694746. [DOI] [PubMed] [Google Scholar]
  2. Bailey L. R., Roodi N., Dupont W. D., Parl F. F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998 Nov 15;58(22):5038–5041. [PubMed] [Google Scholar]
  3. Barrett-Connor E. Postmenopausal estrogen and the risk of breast cancer. Ann Epidemiol. 1994 May;4(3):177–180. doi: 10.1016/1047-2797(94)90094-9. [DOI] [PubMed] [Google Scholar]
  4. Brett K. M., Madans J. H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol. 1997 Mar 15;145(6):536–545. doi: 10.1093/oxfordjournals.aje.a009142. [DOI] [PubMed] [Google Scholar]
  5. Col N. F., Eckman M. H., Karas R. H., Pauker S. G., Goldberg R. J., Ross E. M., Orr R. K., Wong J. B. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997 Apr 9;277(14):1140–1147. [PubMed] [Google Scholar]
  6. Colditz G. A., Egan K. M., Stampfer M. J. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993 May;168(5):1473–1480. doi: 10.1016/s0002-9378(11)90784-4. [DOI] [PubMed] [Google Scholar]
  7. Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Manson J. E., Stampfer M. J., Hennekens C., Rosner B., Speizer F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589–1593. doi: 10.1056/NEJM199506153322401. [DOI] [PubMed] [Google Scholar]
  8. Elledge R. M., Clark G. M., Chamness G. C., Osborne C. K. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 4;86(9):705–712. doi: 10.1093/jnci/86.9.705. [DOI] [PubMed] [Google Scholar]
  9. Folsom A. R., Mink P. J., Sellers T. A., Hong C. P., Zheng W., Potter J. D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995 Aug;85(8 Pt 1):1128–1132. doi: 10.2105/ajph.85.8_pt_1.1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Holmes-Rovner M., Padonu G., Kroll J., Breer L., Rovner D. R., Talarczyk G., Rothert M. African-American women's attitudes and expectations of menopause. Am J Prev Med. 1996 Sep-Oct;12(5):420–423. [PubMed] [Google Scholar]
  11. Hutchinson R. G., Watson R. L., Davis C. E., Barnes R., Brown S., Romm F., Spencer J. M., Tyroler H. A., Wu K. Racial differences in risk factors for atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities. Angiology. 1997 Apr;48(4):279–290. doi: 10.1177/000331979704800401. [DOI] [PubMed] [Google Scholar]
  12. Lip G. Y., Beevers G., Zarifis J. Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians' viewpoint. J Intern Med. 1995 Nov;238(5):389–399. doi: 10.1111/j.1365-2796.1995.tb01216.x. [DOI] [PubMed] [Google Scholar]
  13. Lobo R. A. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 2):982–989. doi: 10.1016/0002-9378(95)90247-3. [DOI] [PubMed] [Google Scholar]
  14. Millikan R. C., Pittman G. S., Tse C. K., Duell E., Newman B., Savitz D., Moorman P. G., Boissy R. J., Bell D. A. Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis. 1998 Nov;19(11):1943–1947. doi: 10.1093/carcin/19.11.1943. [DOI] [PubMed] [Google Scholar]
  15. Moorman P. G., Newman B., Millikan R. C., Tse C. K., Sandler D. P. Participation rates in a case-control study: the impact of age, race, and race of interviewer. Ann Epidemiol. 1999 Apr;9(3):188–195. doi: 10.1016/s1047-2797(98)00057-x. [DOI] [PubMed] [Google Scholar]
  16. Nachtigall L. E. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol. 1990 Apr;75(4 Suppl):77S–83S. doi: 10.1016/0020-7292(90)90537-u. [DOI] [PubMed] [Google Scholar]
  17. Newcomb P. A., Longnecker M. P., Storer B. E., Mittendorf R., Baron J., Clapp R. W., Bogdan G., Willett W. C. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995 Oct 15;142(8):788–795. doi: 10.1093/oxfordjournals.aje.a117717. [DOI] [PubMed] [Google Scholar]
  18. Newman B., Moorman P. G., Millikan R., Qaqish B. F., Geradts J., Aldrich T. E., Liu E. T. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 1995 Jul;35(1):51–60. doi: 10.1007/BF00694745. [DOI] [PubMed] [Google Scholar]
  19. Pham K. T., Grisso J. A., Freeman E. W. Ovarian aging and hormone replacement therapy. Hormonal levels, symptoms, and attitudes of African-American and white women. J Gen Intern Med. 1997 Apr;12(4):230–236. doi: 10.1046/j.1525-1497.1997.012004230.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rosenberg L., Palmer J. R., Rao R. S., Adams-Campbell L. L. Correlates of postmenopausal female hormone use among black women in the United States. Obstet Gynecol. 1998 Mar;91(3):454–458. doi: 10.1016/s0029-7844(97)00699-6. [DOI] [PubMed] [Google Scholar]
  21. Rousseau M. E., McCool W. F. The menopausal experience of African American women: overview and suggestions for research. Health Care Women Int. 1997 May-Jun;18(3):233–250. doi: 10.1080/07399339709516278. [DOI] [PubMed] [Google Scholar]
  22. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud. 1996 Jan-Feb;41(1):11–15. [PubMed] [Google Scholar]
  23. Schairer C., Byrne C., Keyl P. M., Brinton L. A., Sturgeon S. R., Hoover R. N. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control. 1994 Nov;5(6):491–500. doi: 10.1007/BF01831376. [DOI] [PubMed] [Google Scholar]
  24. Sillero-Arenas M., Delgado-Rodriguez M., Rodigues-Canteras R., Bueno-Cavanillas A., Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol. 1992 Feb;79(2):286–294. [PubMed] [Google Scholar]
  25. Smith H. O., Kammerer-Doak D. N., Barbo D. M., Sarto G. E. Hormone replacement therapy in the menopause: a pro opinion. CA Cancer J Clin. 1996 Nov-Dec;46(6):343–363. doi: 10.3322/canjclin.46.6.343. [DOI] [PubMed] [Google Scholar]
  26. Smith R. A., Haynes S. Barriers to screening for breast cancer. Cancer. 1992 Apr 1;69(7 Suppl):1968–1978. doi: 10.1002/1097-0142(19920401)69:7+<1968::aid-cncr2820691718>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  27. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer. Maturitas. 1999 Aug 16;32(3):123–129. doi: 10.1016/s0378-5122(99)00009-2. [DOI] [PubMed] [Google Scholar]
  28. Stanford J. L., Weiss N. S., Voigt L. F., Daling J. R., Habel L. A., Rossing M. A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995 Jul 12;274(2):137–142. [PubMed] [Google Scholar]
  29. Steinberg K. K., Thacker S. B., Smith S. J., Stroup D. F., Zack M. M., Flanders W. D., Berkelman R. L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991 Apr 17;265(15):1985–1990. [PubMed] [Google Scholar]
  30. Weinberg C. R., Sandler D. P. Randomized recruitment in case-control studies. Am J Epidemiol. 1991 Aug 15;134(4):421–432. doi: 10.1093/oxfordjournals.aje.a116104. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES